Eylea Slowed the Progression of Diabetic Retinopathy

Research published in JAMA Ophthalmology shows that anti-vascular endothelial growth factor (VEGF) injections such as Eylea slowed the progression of diabetic retinopathy. However, the injections were not found to significantly slow vision loss more effectively than standard treatments. The results come from two years worth of data in a four-year study.

The researchers are concerned with how many patients receiving Eylea progressed to proliferative diabetic retinopathy (PDR) or center-involved diabetic macular edema (CI-DME). The former is when retinal vessels grow abnormally, while the latter involves fluid leaking out of the retinal blood vessels, threatening vision loss and blindness.

Please reach out to SDCB to learn more about our vision rehabilitation programs and services.

"Therapy Slows Diabetic Retinopathy but Vision Loss Benefit Same as Standard Care"